Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. 17 de mar. de 2019 · We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K...

    • R.D. Lopes, G. Heizer, R. Aronson, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S.G. Goodman, S. ...
    • 2019
  2. 21 de ene. de 2019 · We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K...

  3. 19 de ene. de 2021 · An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.

    • Ziad Hijazi, John H. Alexander, Zhuokai Li, Daniel M. Wojdyla, Roxana Mehran, Christopher B. Granger...
    • 2021
  4. 3 de feb. de 2021 · Most recently, the AUGUSTUS (Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation) trial evaluated the independent effects of the oral anticoagulant apixaban and...

    • Fatima Rodriguez, Robert A. Harrington
    • 2021
  5. 18 de abr. de 2019 · Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an ...

    • R.D. Lopes, G. Heizer, R. Aronson, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S.G. Goodman, S. ...
    • 2019
  6. 2 de jul. de 2019 · AUGUSTUS is the first trial with a two-by-two factorial design in patients with atrial fibrillation (AF) on combined antithrombotic therapy after an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), respectively. 1 Thereby, it allows the independent evaluation of the effects of prescribing apixaban ...

  7. Original Investigation. May 25, 2022. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke A Post Hoc Analysis From the AUGUSTUS Trial.